Last 12 months
Inside the activity.
0 purchase rows · 39 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 6 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 21 |
| Apr 2026 | 0 | 7 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2020 Filed Feb 19, 2020 21:50 UTC |
Schenkein David PDirector
|
Tax withholdingCommon stock | 2,534 | $52.01 | $131,793.34 |
DisclosureSEC source: 0001439222-20-000015 · wf-form4_158214903584597.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,158 Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 16:55 UTC |
Alenson CarmanPrincipal Accounting Officer
|
Exercise / conversionRestricted stock units · Derivative | 2,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · derivative · entry 8 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F6 · derivative.exercise_date: All of the restricted stock units will vest on February 16, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F6 · derivative.expiration_date: All of the restricted stock units will vest on February 16, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 16:55 UTC |
Alenson CarmanPrincipal Accounting Officer
|
Exercise / conversionRestricted stock units · Derivative | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · derivative · entry 7 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 790 Underlying: Common stock · 790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F5 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 16:55 UTC |
Alenson CarmanPrincipal Accounting Officer
|
Exercise / conversionCommon stock | 2,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · nonDerivative · entry 2 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 16:55 UTC |
Alenson CarmanPrincipal Accounting Officer
|
Exercise / conversionCommon stock | 790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 21:53 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionRestricted stock unit · Derivative | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000018 · wf-form4_158214922111232.xml · derivative · entry 5 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common stock · 2,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 21:53 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionCommon stock | 2,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000018 · wf-form4_158214922111232.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 21:51 UTC |
Hirsch AndrewChief Financial Officer
|
Exercise / conversionRestricted stock units · Derivative | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000016 · wf-form4_158214909552275.xml · derivative · entry 5 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common stock · 2,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 21:51 UTC |
Hirsch AndrewChief Financial Officer
|
Exercise / conversionCommon stock | 2,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000016 · wf-form4_158214909552275.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 21:50 UTC |
Schenkein David PDirector
|
Exercise / conversionRestricted stock units · Derivative | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000015 · wf-form4_158214903584597.xml · derivative · entry 5 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,125 Underlying: Common stock · 8,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 21:50 UTC |
Schenkein David PDirector
|
Exercise / conversionCommon stock | 8,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000015 · wf-form4_158214903584597.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 16:55 UTC |
Alenson CarmanPrincipal Accounting Officer
|
GrantStock option (right to buy) · Derivative | 5,332 | $0.00 Strike: $51.51 | $0.00 |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · derivative · entry 6 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,332 Underlying: Common stock · 5,332 shares Expires 2030-02-14 F4 · derivative.exercise_date: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 16:55 UTC |
Alenson CarmanPrincipal Accounting Officer
|
GrantRestricted stock unit · Derivative | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · derivative · entry 5 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Underlying: Common stock · 4,800 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. The shares underlying the restricted stock units will vest in full on February 14, 2022. F3 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. The shares underlying the restricted stock units will vest in full on February 14, 2022. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 16:55 UTC |
Alenson CarmanPrincipal Accounting Officer
|
GrantRestricted stock units · Derivative | 2,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000019 · wf-form4_158214930367652.xml · derivative · entry 4 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666 Underlying: Common stock · 2,666 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:53 UTC |
Bowden ChristopherChief Medical Officer
|
GrantStock option (right to buy) · Derivative | 45,000 | $0.00 Strike: $51.51 | $0.00 |
DisclosureSEC source: 0001439222-20-000018 · wf-form4_158214922111232.xml · derivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common stock · 45,000 shares Expires 2030-02-14 F3 · derivative.exercise_date: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:53 UTC |
Bowden ChristopherChief Medical Officer
|
GrantRestricted stock units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000018 · wf-form4_158214922111232.xml · derivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:52 UTC |
FOUSE JACQUALYN ADirector · Chief Executive Officer
|
GrantRestricted stock units · Derivative | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000017 · wf-form4_158214915116382.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common stock · 34,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:52 UTC |
FOUSE JACQUALYN ADirector · Chief Executive Officer
|
GrantStock option (right to buy) · Derivative | 137,000 | $0.00 Strike: $51.51 | $0.00 |
DisclosureSEC source: 0001439222-20-000017 · wf-form4_158214915116382.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,000 Underlying: Common stock · 137,000 shares Expires 2030-02-14 F1 · derivative.exercise_date: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:51 UTC |
Hirsch AndrewChief Financial Officer
|
GrantStock option (right to buy) · Derivative | 45,000 | $0.00 Strike: $51.51 | $0.00 |
DisclosureSEC source: 0001439222-20-000016 · wf-form4_158214909552275.xml · derivative · entry 4 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common stock · 45,000 shares Expires 2030-02-14 F3 · derivative.exercise_date: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:51 UTC |
Hirsch AndrewChief Financial Officer
|
GrantRestricted stock units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000016 · wf-form4_158214909552275.xml · derivative · entry 3 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2020 Filed Feb 28, 2020 21:18 UTC |
MARAGANORE JOHNDirector
|
GiftCommon stock | 1,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000026 · wf-form4_158292472045446.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,294 F1 · kind: This disposition reflects a gift of shares to a not-for-profit organization. Read SEC document |
| February 14, 2020 Filed Feb 28, 2020 21:18 UTC |
MARAGANORE JOHNDirector
|
GiftCommon stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000026 · wf-form4_158292472045446.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,209 F1 · kind: This disposition reflects a gift of shares to a not-for-profit organization. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:05 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 7,100 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001439222-20-000008 · wf-form4_158205991627413.xml · derivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,306 Underlying: Common stock · 7,100 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:05 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 7,100 | $50.16 | $356,111.86 |
DisclosureSEC source: 0001439222-20-000008 · wf-form4_158205991627413.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.82. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:05 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionCommon stock | 7,100 | $35.16 | $249,636.00 |
DisclosureSEC source: 0001439222-20-000008 · wf-form4_158205991627413.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:21 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 621 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001439222-20-000006 · wf-form4_158162886617100.xml · derivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,406 Underlying: Common stock · 621 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:21 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 621 | $50.02 | $31,063.23 |
DisclosureSEC source: 0001439222-20-000006 · wf-form4_158162886617100.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.06. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:21 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionCommon stock | 621 | $35.16 | $21,834.36 |
DisclosureSEC source: 0001439222-20-000006 · wf-form4_158162886617100.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 05, 2020 Filed Feb 6, 2020 21:52 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 35,447 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001439222-20-000005 · wf-form4_158102593034853.xml · derivative · entry 6 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,027 Underlying: Common stock · 35,447 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 05, 2020 Filed Feb 6, 2020 21:52 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionCommon stock | 35,447 | $35.16 | $1,246,316.52 |
DisclosureSEC source: 0001439222-20-000005 · wf-form4_158102593034853.xml · nonDerivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:52 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 8,526 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001439222-20-000005 · wf-form4_158102593034853.xml · derivative · entry 5 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,474 Underlying: Common stock · 8,526 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:52 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 35,447 | $50.10 | $1,776,025.85 |
DisclosureSEC source: 0001439222-20-000005 · wf-form4_158102593034853.xml · nonDerivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.46. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:52 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 14,191 | $50.03 | $709,962.96 |
DisclosureSEC source: 0001439222-20-000005 · wf-form4_158102593034853.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.23. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:52 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionCommon stock | 8,526 | $35.16 | $299,774.16 |
DisclosureSEC source: 0001439222-20-000005 · wf-form4_158102593034853.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 77 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:24 UTC |
Car BruceChief Scientific Officer
|
GrantRestricted stock units · Derivative | 10,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000003 · wf-form4_157851867389419.xml · derivative · entry 2 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,311 Underlying: Common stock · 10,311 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 6, 2020. Beginning on January 6, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on January 6, 2020. Beginning on January 6, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:24 UTC |
Car BruceChief Scientific Officer
|
GrantStock option (right to buy) · Derivative | 47,007 | $0.00 Strike: $48.49 | $0.00 |
DisclosureSEC source: 0001439222-20-000003 · wf-form4_157851867389419.xml · derivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,007 Underlying: Common stock · 47,007 shares Expires 2030-01-06 F1 · derivative.exercise_date: This option was granted on January 6, 2020. The shares underlying this option vest as to 25% of the underlying shares on January 6, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 26, 2019 Filed Dec 30, 2019 16:08 UTC |
Alenson CarmanPrincipal Accounting Officer
|
SaleCommon stock | 2,950 | $50.09 | $147,765.50 |
DisclosureSEC source: 0001439222-19-000030 · wf-form4_157774008262318.xml · nonDerivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.04 to $50.58. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares purchased through the Company's employee stock purchase plan. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:07 UTC |
Biller JonathanChief Legal Officer
|
GrantRestricted stock units · Derivative | 17,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-19-000028 · wf-form4_157558005250284.xml · derivative · entry 2 Biller Jonathan · CIK 0001744749 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,259 Underlying: Common stock · 17,259 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:07 UTC |
Biller JonathanChief Legal Officer
|
GrantStock option (right to buy) · Derivative | 78,824 | $0.00 Strike: $39.11 | $0.00 |
DisclosureSEC source: 0001439222-19-000028 · wf-form4_157558005250284.xml · derivative · entry 1 Biller Jonathan · CIK 0001744749 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,824 Underlying: Common stock · 78,824 shares Expires 2029-12-03 F1 · derivative.exercise_date: This option was granted on December 3, 2019. The shares underlying this option vest as to 25% of the underlying shares on December 3, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:05 UTC |
FOUSE JACQUALYN ADirector · Chief Executive Officer
|
PurchaseCommon stock | 40,322 | $31.00 | $1,249,982.00 |
DisclosureSEC source: 0001439222-19-000025 · wf-form4_157385189418467.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,722 F1 · price: All shares were purchased at $31.00 per share in an underwritten public offering that closed on November 13, 2019. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:03 UTC |
Schenkein David PDirector
|
PurchaseCommon stock | 8,064 | $31.00 | $249,984.00 |
DisclosureSEC source: 0001439222-19-000023 · wf-form4_157385177050441.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,567 F1 · price: All shares were purchased at $31.00 per share in an underwritten public offering that closed on November 13, 2019. Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 16:06 UTC |
CELGENE CORP /DE/10% owner
Celgene European Investment Co LLC10% owner
Celgene Switzerland LLC10% owner
Celgene Alpine Investment Co., LLC10% owner
|
PurchaseCommon Stock | 403,225 | $31.00 | $12,499,975.00 |
DisclosureSEC source: 0001104659-19-064171 · tm1922788d1_4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner Celgene European Investment Co LLC · CIK 0001577650 · 10% owner Celgene Switzerland LLC · CIK 0001661486 · 10% owner Celgene Alpine Investment Co., LLC · CIK 0001581774 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,777,824 Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:20 UTC |
MARAGANORE JOHNDirector
|
GiftCommon stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-19-000011 · wf-form4_156054363018449.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,609 F1 · kind: This disposition reflects a gift of 5,000 shares to a not-for-profit organization. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:07 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 7,218 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001628280-19-007955 · wf-form4_156045644678438.xml · derivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 7,218 shares Expires 2022-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares, and the remaining 15,909 shares vested on April 4, 2015. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:07 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionCommon stock | 7,218 | $2.34 | $16,872.08 |
DisclosureSEC source: 0001628280-19-007955 · wf-form4_156045644678438.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:08 UTC |
MARAGANORE JOHNDirector
|
Exercise / conversionRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033625 · doc4.xml · derivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:08 UTC |
MARAGANORE JOHNDirector
|
Exercise / conversionCommon stock | 1,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-033625 · doc4.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:08 UTC |
Scadden DavidDirector
|
Exercise / conversionRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033626 · doc4.xml · derivative · entry 4 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:08 UTC |
Scadden DavidDirector
|
Exercise / conversionCommon stock | 1,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-033626 · doc4.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:07 UTC |
Ho MaykinDirector
|
Exercise / conversionRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033622 · doc4.xml · derivative · entry 4 Ho Maykin · CIK 0001646395 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.